Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857996 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
A Phase 2 study, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT04857996 is a Phase 2 study that has completed, run by Unity Biotechnology. The registered enrollment target is 65 participants.
The verdict
NCT04857996, a Phase 2 study, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in patients with diabetic macular edema (DME).
Interventions
- OTHER Sham
- DRUG UBX1325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-06-25 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857996
The ClinicalTrials.gov registry entry for NCT04857996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Unity Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT04857996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857996 about?
NCT04857996 is a clinical study titled "Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)". This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in patients with diabetic macular edema (DME).
What is the current status of trial NCT04857996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2021-06-25. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT04857996?
The interventions under investigation include: Sham (OTHER), UBX1325 (DRUG).
Who is sponsoring clinical trial NCT04857996?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.